40 kilograms of “Magic” Psilocybin Mushrooms will be dried and shipped to Mydecine’s Canadian Current Good Manufacturing Practice facility, which has a Health Canada Schedule 1 Dealer’s License attached to it, allowing for legal import/export, research and development, cultivation, and commercial sale of active psychedelic medicinal compounds.

As an emerging BioPharma and life sciences company, Mydecine is currently researching and developing alternative natural medicines and constructing a drug pipeline for the psychedelic industry. Bought stock offering with Canaccord will increase Mydecine capital by almost 20 million dollars!